Ovid Therapeutics Inc.: net finite-lived intangible assets
Net finite-lived intangible assets for Ovid Therapeutics Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Ovid Therapeutics Inc. financial histories
What this measure means
Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.
Exact concept: us-gaap:FiniteLivedIntangibleAssetsNet. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2016-12-31 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 0 | USD | 2026-03-18 | 10-K · 0001628280-26-019438 |
| At date | 2024-12-31 | 100,000 | USD | 2026-03-18 | 10-K · 0001628280-26-019438 |
| At date | 2023-12-31 | 200,000 | USD | 2025-03-11 | 10-K · 0001628280-25-011844 |
| At date | 2022-12-31 | 222,100 | USD | 2024-03-08 | 10-K · 0001628280-24-009809 |
| At date | 2021-12-31 | 164,092 | USD | 2023-03-13 | 10-K · 0001628280-23-007648 |
| At date | 2020-12-31 | 319,000 | USD | 2022-03-15 | 10-K · 0000950170-22-003668 |
| At date | 2019-12-31 | 467,000 | USD | 2021-03-15 | 10-K · 0001564590-21-013016 |
| At date | 2018-12-31 | 392,000 | USD | 2020-03-11 | 10-K · 0001564590-20-010108 |
| At date | 2017-12-31 | 124,194 | USD | 2019-03-07 | 10-K · 0001564590-19-006804 |
| At date | 2016-12-31 | 110,074 | USD | 2018-03-29 | 10-K · 0001564590-18-007152 |
Related financial histories
- Ovid Therapeutics Inc.: total assets
- Ovid Therapeutics Inc.: total liabilities
- Ovid Therapeutics Inc.: stockholders equity
- Ovid Therapeutics Inc.: cash and cash equivalents
- Ovid Therapeutics Inc.: net income or loss
- Ovid Therapeutics Inc.: operating cash flow
- Ovid Therapeutics Inc.: capital expenditure payments
- Ovid Therapeutics Inc.: contract revenue excluding tax
- Ovid Therapeutics Inc.: financing cash flow
- Ovid Therapeutics Inc.: investing cash flow
- Ovid Therapeutics Inc.: retained earnings or deficit
- Ovid Therapeutics Inc.: basic weighted-average shares
- Ovid Therapeutics Inc.: diluted weighted-average shares
- Ovid Therapeutics Inc.: basic earnings per share
- Ovid Therapeutics Inc.: diluted earnings per share
- Ovid Therapeutics Inc.: income tax expense or benefit
- Ovid Therapeutics Inc.: net property, plant and equipment
- Ovid Therapeutics Inc.: share-based compensation expense
- Ovid Therapeutics Inc.: operating income or loss
- Ovid Therapeutics Inc.: current assets
- Ovid Therapeutics Inc.: current liabilities
- Ovid Therapeutics Inc.: current accounts payable
- Ovid Therapeutics Inc.: operating expenses
- Ovid Therapeutics Inc.: research and development expense
Inspect the source
- Entity
- Ovid Therapeutics Inc. / CIK 0001636651
- Captured
- 2026-09-21T17:21:21.098Z
- SEC response SHA-256
b4de1e66c6e8e0453b1f8d4fc2f1dafe6798859207cf5a42629d88fe4c5e512a
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001636651.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))